Reported about 17 hours ago
US pharmaceutical companies are increasingly licensing experimental drugs from China, betting that these investments, often starting at $80 million, could yield multibillion-dollar returns. In the first half of 2025, US firms signed 14 licensing deals worth an estimated $18.3 billion, a sharp increase from only two deals the previous year. As many drugs lose patent protection, US companies are seeking high-quality, affordable assets from China to fill their pipelines, reflecting China's growing role in global drug development. Analysts predict a continued rise in these licensing agreements, viewing China's biotech sector as an emerging competitor.
Source: YAHOO